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Abstract
Background: Autoimmunity appears to be associated with the pathophysiology of Meniere’s disease (MD), an inner ear
disorder characterized by episodes of vertigo associated with hearing loss and tinnitus. However, the prevalence of
autoimmune diseases (AD) in patients with MD has not been studied in individuals with uni or bilateral sensorineural
hearing loss (SNHL).
Methods and Findings: We estimated the prevalence of AD in 690 outpatients with MD with uni or bilateral SNHL from
otoneurology clinics at six tertiary referral hospitals by using clinica criteria and an immune panel (lymphocyte populations,
antinuclear antibodies, C3, C4 and proinflammatory cytokines TNFa, INFc). The observed prevalence of rheumatoid arthritis
(RA), systemic lupus erythematosus (SLE) and ankylosing spondylitis (AS) was higher than expected for the general
population (1.39 for RA, 0.87 for SLE and 0.70 for AS, respectively). Systemic AD were more frequently observed in patients
with MD and diagnostic criteria for migraine than cases with MD and tension-type headache (p=0.007). There were clinical
differences between patients with uni or bilateral SNHL, but no differences were found in the immune profile. Multiple
linear regression showed that changes in lymphocytes subpopulations were associated with hearing loss and persistence of
vertigo, suggesting a role for the immune response in MD.
Conclusions: Despite some limitations, MD displays an elevated prevalence of systemic AD such as RA, SLE and AS. This
finding, which suggests an autoimmune background in a subset of patients with MD, has important implications for the
treatment of MD.
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Introduction
Meniere’s disease (MD) is a chronic disorder affecting the inner
ear characterized by fluctuating sensorineural hearing loss
(SNHL), episodes of vertigo lasting from 20 minutes to hours,
tinnitus, and aural fullness [1]. Phenotypic heterogeneity is
observed in patients with MD and it is difficult to define the
outcome in early stages of the disease. Although the frequency of
the attacks of vertigo is usually greater in the first few years of the
disease, and it diminished at advances stages of MD [2,3], balance
problems persist along the disease and may become severe if
patients develop a bilateral vestibular hypofunction.
Hearing loss can be observed in one or both ears. The
prevalence of bilaterality is around 25–40%, being dependent
upon the follow-up period, and the risk of developing bilateral MD
for a patient with unilateral disease has been estimated 14% [4].
Usually, SNHL starts in one ear and it can appear in the second
ear after a mean interval of 7 years (range: 2 months 227 years)
[4], and bilateral SNHL has a significant impact in health-related
quality of life in MD [5].
Autoimmune mechanisms appear to be associated with the
pathophysiology of MD [6,7]. The evidences that support this
hypothesis include: the association with alleles of DRB1 gene of
the MHC reported in different populations [8,9]; the finding of
elevated levels of autoantibodies or circulating immune complexes
(CIC) in the serum of some patients [7,10,11]; the experimental
induction of hydrops by injection of antigens or monoclonal
antibodies in the guinea pig [12] and the association with a
functional variant of LYP, a lymphoid protein phosphatase, which
inhibits T cell receptors response in patients with bilateral ear
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antibodies (ANA), antiphospholipid antibodies and antibodies
against a 68 kD protein have been studied in small series of
patients with MD, showing conflicting results [6,7,14–17].
However, the prevalence of autoimmune disease (AD) in patients
with MD or the role of lymphocyte subpopulations and cytokines
such as TNFa and INFc has seldom been investigated in patients
with MD [17].
The aim of this study is to estimate the prevalence of AD in
patients with MD and to evaluate an immune panel among
patients wih MD and unilateral or bilateral SNHL.
Methods
Subjects
A case series of 690 adult patients (217 bilateral, 473 unilateral
disease) with a clinical diagnosis of definite MD according to the
diagnostic scale of the American Academy of Otolaryngology-
Head and Neck Surgery (AAO-HNS) were included from October
2007 to May 2011 [18]. We selected patients with bilateral SNHL
in a higher percentage than it is observed in most clinics to reach
enough number of patients to be compared with unilateral MD.
All were outpatients regularly followed up at the Otoneurology
Clinics at six tertiary referral centers that recruited patients for this
study. The information was obtained by means of a standardized,
structured clinical database designed for follow-up in patients with
MD [19]. When patients agreed to participate in the study, they
were informed that they must provide information about the
number and duration of episodes of vertigo, headache and hearing
loss they had experienced in the last six months. The interview was
oriented to identify the type of headache and if the patient
reported symptoms suggesting an autoimmune condition.
All patients underwent complete otolaryngologic examina-
tion and audiologic evaluation with pure-tone audiometry and
tympanometry. A neurotologic examination including nystagmus
in the primary position, gaze-evoked and head-shaking nystagmus
and standard bithermal caloric test was also performed. Hearing
staging for each patient with definite MD was defined as the mean
of four-tone average of 0.5, 1, 2 and 3 kHz according to the AAO-
HNS criteria: stage 1, #25 dB; stage 2, 26–40 dB; stage 3, 41–
70 dB; 4, stage 4, .75 db [18]. Patients with bilateral SNHL were
considered to have metachronic SNHL if a period of time
.1month to develop SNHL between the first and the second ear
was observed. Individuals with simultaneous SNHL in both ears
were considered to have synchronic SNHL. Episodes of vertigo
were characterized by their frequency and duration as previously
described [16], and episodes of vertigo lasting less than 20 minutes
or the sensation of instability usually observed in these patients
were not considered in this study. The protocol of diagnosis
included an examination by magnetic resonance imaging of the
brain to exclude other possible causes of neurotological symptoms.
Ethics
The subject’s written informed consent was obtained to
participate in the study according to the Helsinki guidelines and
the Hospital de Poniente Institutional Review Board approved the
study. The clinical features of a subset of 89 patients with MD
from Almeria in our series were previously reported [9].
Immunoserological assessment
Antinuclear antibodies (ANA) were detected on Hep-2 cells by
indirect immunofluorescence method. Titers of 1/160 were consid-
ered positive. We also used a qualitative enzyme-linked immunosor-
bent assay (ELISA) for the detection of ANAs (DIASTAT). It detects
ANAs against Sm, Sm/RNP, Ro (SS-A), La (SS-B), Scl-70, Jo-1,
dsDNA histone and centromere antigens. Serum concentrations of
extractable nuclear antigens (ENAs) were detected by EliA Symphony
(Pharmacia Diagnostics, Freiburg, Germany), an ENA screening
which detects the following autoantibodies: SSA/Ro, SSB/La,
U1RNP (A, C), RNP70, Scl-70, JO-1, centromere B and Sm. Also,
anti-dsDNA were measured by EliA dsDNA (Pharmacia Diagnostics,
Freiburg, Germany).
Serum complement proteins C3 and C4 and immunoglobulins
(IgG, IgM, IgA) were measured by an immunoturbidimetric assay
on an Olympus AU5400 analyzer.
A C1q binding ELISA kit (HYCOR, Agilent Technologies,
Amstelveen, The Netherlands) was used to determine Circulating
Immune Complexes (CIC) concentrations in patients with MD in
a Hytec 288 Plus System (HYCOR). Values higher than +3S Do f
the mean normal cutoff point were considered positive.
Peripheral lymphocyte populations were characterized by an
EPICS XL-MLC flow cytometer (Coulter). Fluorescent dyes used
were CD3-PC5/CD4-FITC/CD8-PE.
Determination of serum soluble cytokines
Serum interferon-c (IFN-c) and tumor necrosis factor-a (TNF-
a) were measured by an ELISA kit (Biosource TM, Nivelles,
Belgium) using an ELISA plate reader (Menarini Diagnostics)
according to manufacturer’s instructions. The intraassay and
interassay coefficients of variation, respectively, were 1.8% and
2.3% for IFN-c, 0.9% and 1.6% for TNF-a. All analytical
determinations were performed in the quiescent phase (at least 4
weeks since the last episode of vertigo).
Table 1. Clinical variables of 690 patients with MD according to the center of origin.
CENTERS Age
{ Age of onset
{ Gender (% women)
Bilateral sensorineural
hearing loss
Follow-up period .10
years (%)
Almeria (n=150) 56.6612.6 46.6612.6 61.3 42.7 51 (34)
Badajoz (n=104) 53.4613.6 46.3615.2 51.0 9.6 33 (32)
Pontevedra (n=127) 54.4612.5 46.3612.4 71.7 30.7 40 (31)
Salamanca (n=99) 53.9612.5 45.9612.3 60.6 47.5 29 (29)
Santiago (n=155) 54.0613.8 45.5614.4 54.2 41.9 55 (35)
Valencia (n=55) 59.4613.5 44.1615.1 41.8 41.9 36 (65)
P value 0.042 0.884 0.001 2.1610
28
{Mean 6 Standard deviation.
doi:10.1371/journal.pone.0026759.t001
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The clinical records of all patients were reviewed to retrieve
additional information not included in the clinical database.
Some patients were visited several times to obtain all clinical and
analytical variables of the protocol. The following variables were
assessed: sociodemographics (sex, age), clinical (age of onset, uni/
bilateral disease, ear affected, hearing loss at diagnosis, AAO-HNS
hearing stage, class (frequency of vertigo during the last six
months), Tumarkin crisis and functional scale, duration of attacks,
time- course of the disease, time since last attack) and associated
factors (headache, type of headache, history of AD, smoking and
coffee drinking). Diagnosis of AD was performed by a rheuma-
tologist or Internal Medicine specialist, according to the criteria
defined by the American College of Rheumatology (http://mail3.
rheumatology.org/practice/index.asp). Diagnosis of migraine and
tension-type headache was performed according to the Interna-
tional Classification of Headache Disorders [20].
Exclusion criteria
We excluded patients with vestibular migraine, benign parox-
ysmal positional vertigo, vestibular neuritis, head trauma, ear
surgery, recurrent infection of the middle ear, acoustic schwan-
noma and any known cause mimicking MD, according to the
diagnostic scale of the AAO-HNS [18].
Statistical analysis
Data are shown as means with standard deviations (SD).
Qualitative variables were compared between unilateral and
bilateral MD by using Pearson Chi-square with Yates’ continuum
correction; Fisher’s test was calculated when the number of cases
per cell was ,5. Quantitative variables (age, time-course and time
since last attack) were compared by unpaired student’s T test. The
time-course of hearing stage, episodes of vertigo and Tumarkin
crisis were detemined according to the Kaplan-Meier method, and
survival curves were compared using the log-rank test.
Bivariate regression analysis was used to search for associa-
tion between clinical and analytical factors and hearing loss and
frequency of vertigo. Using pure tone average hearing loss and the
frecuency of vertigo in the last six months as dependent variables,
we carried out several multiple linear regression models (forward
method) to investigate the factors associated with hearing loss and
the frequency of vertigo in patients with MD. Statistical signifi-
cance was accepted at p,0.05.
Results
Clinical differences in patients with uni and bilateral
SNHL
The patients in this series showed no differences in age at
inclusion or the age of onset of disease (Table 1). However, the
percentage of women included in each center was different (range
42–72, p=0.001). Moreover, although the percentage of patients
with bilateral SNHL was different in each center (range 10–47,
p=2.1610
28), they do not represent the real percentage of uni or
bilateral MD observed in each clinics.
We compared the clinical phenotype in patients with unilateral
and bilateral SNHL with at least 5 years since the onset of
symptoms (n=466, Table 2). Hearing loss at diagnosis was sig-
nificantly worst in patients with bilateral SNHL when they were
compared with unilateral MD (p=2.9610
26). Migraine was not
found more common in patients with uni or bilateral SNHL
(p=0.88). In addition, no differences were found in the frequency
of reported rheumatic diseases, smoking or coffee consumption
between patients with unilateral or bilateral SNHL. Hearing stage
and functional level were worst in individuals with bilateral
hearing loss (p=5.2610
28 and 0.004, respectively).
The vertigo status was assessed in a cohort of 673 patients
(444 unilateral and 229 bilateral). The median duration of
recurrent vertigo was 10 years (95% confidence interval, 8.56–
11.44) in patients with unilateral MD; however, the median
duration of recurrent vertigo in patients with bilateral MD was
significantly longer (12 years (10.4–13.6), log-rank test,
p=0.03; Fig. 1A). The time-course of hearing stage was also
examined in 611 patients (403 unilateral and 208 bilateral).
The median of years to reach stage 4 (.75 dB) was 27 and 24
years in patients with unilateral and bilateral SNHL, respec-
tively (log-rank test, p=0.36; Fig. 1B).
Table 2. Clinical phenotype in 466 patients with MD with at
least 5 years since the onset of the disease.
VARIABLES
BILATERAL
(n=191)
UNILATERAL
(n=275) P value
Age of onset (SD) 45 (14) 44 (12) 0,64
Gender (% women) 55.0 57.4 0.60
Affected ear (%) 40.3 Left, 32.0
Right 27.7
Hearing loss at
diagnosis*, mean (SD)
59.3 (15.7) 49.9 (19.3) 2.9610
26
Headache, n (%) 65 (38) 77(31) 0.17
Migraine, n (%) 20 (10) 30 (11) 0.88
Rheumatoid history,
n( % )
28 (15) 35 (13) 0.83
Smoking, n (%) 37 (19) 62 (23) 0.11
Coffee drinking n (%) 39 (20) 54 (20) 0.92
Hearing stage, n (%) Worst ear Affected ear
1 3 (2) 25 (10)
2 37 (22) 84 (34)
3 85 (50) 106 (43)
4 46 (27) 30 (12)
Time-course (years)
mean +/2 SD
13681 1 67 0.002
Hearing stage**,
mean (SD)
3.0 (0.7) 2.6 (0.8) 5.2610
28
Class, n (%)
A 66 (35) 120 (44) 0.05
B or C 125 (65) 155 (56)
Tumarkin crisis n (%) 27 (25) 31 (19) 0.23
Functional scale, n (%)
1 32 (18) 47 (19) 0.004
2 44 (25) 81 (33)
3 37 (21) 58 (23)
4 27 (16) 42 (17)
5 22 (13) 6 (2)
6 4 (2) 3 (1)
*Pure tone avarage (PTA, hearing loss at diagnosis) and time-course were
compared by unpaired Student’s t test. The rest of qualitative variables were
compared by Chi-squared test.
**Hearing stage calculated for the worst ear in bilateral MD.
doi:10.1371/journal.pone.0026759.t002
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hearing stage 4 was used to compare hearing loss progression among patients with uni or bilateral MD (B, log-rank test, p=0.36).
doi:10.1371/journal.pone.0026759.g001
Table 3. Autoimmune diseases diagnosis found among 575 patients with MD
{.
Disease Unilateral (N=378) Bilateral (N=197) TOTAL Prevalence
Rheumatoid arthritis 5 3 8 1,39
Psoriasic arthritis 1 0 1 0,17
Oligoarthritis 1 0 1 0,17
Ankylosing spondilytis 0 4 4 0,70
Paget disease 1 0 1 0,17
Rheumatic polymialgia 1 1 2 0,35
Systemic lupus erythematosus 4 1 5 0,87
Sjogren Syndrome 2 1 3 0,52
Autoimmune hypothyroidism 7 0 7 1,22
Graves disease 2 2 4 0,70
Autoimmune thyroiditis 2 0 2 0,35
Type I diabetes 1 1 2 0,35
Autoimmune thrombocytopenia 1 0 1 0,17
Primary liver cirrosis 1 0 1 0,17
Autoimmune hepatitis 0 1 1 0,17
Ulcerative colitis 2 1 3 0,52
Rheumatoid fever 2 0 2 0,35
Neumonitis 1 0 1 0,17
Sarcoidosis 0 1 1 0,17
Psoriasis 1 3 4 0,70
Undetermined 4 5 9 1,57
Overall, N 39 24 63
Prevalence 10,29 12,18 10,95
{Bold values are higher than expected in the general population.
doi:10.1371/journal.pone.0026759.t003
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AD was assessed in a subset of 575 patients in our series
(Table 3). Eight patients had rheumatoid arthritis (RA), five were
diagnosed of systemic lupus erythematosus (SLE) and four subjects
had ankylosing spondylitis (AS). The estimated prevalence of these
systemic AD in our series of MD was 1.39 for RA, 0.87 for SLE
and 0.70 for AS. The rest of immune conditions were observed
with the same frequency that expected in the general population in
Caucasians. The overall estimated prevalence of ADs did not
differ between patients with uni or bilateral SNHL (p=0.17).
However, AD were most commonly observed among patients with
migraine than subjects with tension-type headache (p=0.007).
There were 72 patients with migraine and MD in our cohort, and
19 of them (26%) of had a diagnosis of an AD. However, only 10
of 98 (10%) patients with tension-type headache has AD.
Immunological profile in patients with MD
Immunological testing did not found differences for ANA, C3,
C4, CIC, IgG, IgM, IgA or lymphocytes population between
patients with MD and uni or bilateral SNHL (Table 4). Serum
levels of TNFa and INFc were not different from controls in either
unilateral or bilateral MD (Table 5).
Predictive factors for hearing loss and vertigo
Two multiple linear regression models were designed by using
hearing stage and the frequency of vertigo as the dependent
variables to determine which factors could explain their variability
(Table 6). Hearing stage depended upon bilaterality, hearing loss
at diagnosis and lymphocyte T (CD19) cells (R
2=0.52, p=0.01).
In addition, patients who reported vertigo in the last six months
showed a significant association with the score in the functional
scale, lymphocyte B (CD8) cells and complement factor C4
(R
2=0.12, p=0.05).
Discussion
The frequency of vertigo attacks and the SNHL are the most
remarkable features of MD and they show a significant variability
among patients. We have found an increased prevalence of systemic
AD such as RA, SLE and AS in our series, and an association between
migraine and AD not previously reported in patients with MD.
We have preferred to use the term bilateral SNHL instead of
bilateral MD, since it is difficult to know which ear is causing an
episode of vertigo in cases with synchronic SNHL.
Hearing loss at diagnosis is worse in patients with bilateral
SNHL and this could be explain either by a diagnostic delay of
these cases or by a more severe onset with hearing loss in these
patients. The profile of SNHL was different in patients with
unilateral or bilateral hearing loss, and when hearing levels were
corrected by age, low-tone hearing loss was found in unilateral MD,
buta pantonalhearing loss was observed inbilateral cases[21].This
is a relevant finding, since a pantonal SNHL may be a predictor of
bilateral affectation [21]. Hearing stage was worse for patients with
bilateral SNHL when the worst ear was compared with the affected
ear in individuals with unilateral MD. Since hearing loss fluctuates
in the first years [2,3,22], and some patients can develop the disease
in the second ear, we also compared clinical and immunological
variables in patients with unilateraland bilateral SNHL with at least
15 years since the onset of the disease, to avoid the inclusion of
bilateral cases as unilateral MD (cases which potentially can develop
thedisease inthesecondear). Themean time courseinthesesubsets
Table 4. Comparison of standard immunological variables
between patients with unilateral and bilateral MD.
Total Bilateral Unilateral P value
ANA IIF 1/160 (%) 30/400 (7) 12/153 (8) 18/247(7) 0.85
ANA ELISA (%) 7/71 (10) 3/33 (9) 4/38 (10) 1.00
ENA (%) 14/315 (4) 8/135 (6) 6/180 (3) 0.28
Anti dsDNA 4/116 (3) 2/46 (4) 2/70 (3) 0.65
C3 increase (%) 42/437 (10) 20/171 (12) 22/266 (8) 0.49
C4 increase (%) 55/437 (13) 26/170 (15) 29/267 (11) 0.22
CIC increase (%) 36/422 (8) 17/164 (10) 19/258 (7) 0.28
IgM increase (%) 28/333 (8) 8/127 (6) 20/206 (10) 0.32
IgG increase (%) 8/333 (2) 1/128 (1) 7/205 (3) 0.16
IgA increase (%) 21/315 (7) 7/123 (6) 14/192 (7) 0.84
Lymphocyte
populations
CD4 cells
Low 17/386 (4) 6/158 (4) 11/228 (5) 0.35
Increase 19/386 (5) 5/158 (3) 14/228 (6)
CD8 cells
Low 10/391 (3) 7/160 (4) 3/231 (1) 0.15
Increase 25/391 (7) 9/160 (6) 16/231 (7)
CD16 cells increase 22/192 (11) 9/89 (10) 13/103 (13) 0.35
CD19 cells increase 21/190 (11) 7/86 (8) 14/104 (13) 0.40
CD3 cells increase 27/361 (7) 7/144 (5) 20/217 ( 9) 0.27
doi:10.1371/journal.pone.0026759.t004
Table 5. Comparison of serum TNFa and INFc concentrations
(mean 6 SD) between patients with MD and controls.
Cytokine
Bilateral
(N=29)
Unilateral
(N=44)
Controls
(N=99) P value
TNFa 16.6621.6 11.7619.8 11.1615.0 0.32
INFc 5.066.5 3.763.2 3.563.5 0.25
doi:10.1371/journal.pone.0026759.t005
Table 6. Multiple linear regression analysis for clinical and
immunological variables associated with hearing loss and
frequency of vertigo in MD.
Symptom Factor R
2 R
2 corrected B p value
Hearing loss (Constant) 0.52 0.51 0.41 0.021
N=186 1 Bilateral
hearing loss
0.47 8.6610
26
2 Hearing loss
at diagnosis
0.03 1.5610
218
3 CD19 cells
increase
20.36 0.010
Vertigo (Constant) 0.12 0.11 0.30 2.9610
28
N=365 1 Functional level 0.11 5.1610
210
2 CD8 cells
increase
20.20 0.015
3 C4 increase 0.30 0.054
B is the coefficient of regression.
doi:10.1371/journal.pone.0026759.t006
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suggesting that after 20 years of the disease the mean SNHL seems
to be the same in all patients.
Headache is a common complaint in these patients either with
uni or bilateral hearing loss, but patients with a clinical diagnosis of
migraine according to the IHS criteria was observed with the same
frequency as described in the general population, confirming the
findings in a recent wide epidemiologic study [23]. Our current
data do not support the hypothesis that migraine is more frequent
in patients with bilateral SNHL.
Previous studies have shownthatthenumber of episodes of vertigo is
greater in the first few years of the disease [2,3,19], and the number of
patients without episodes of vertigo increases with time [19]. However,
these studies did not include enough number of patients with bilateral
SNHL to investigate clinical differences between uni and bilateral MD.
Our study shows differences in the number of years with episodes
of vertigo between patients with unilateral and bilateral SNHL.
Vertigo attacks last two more years in patients with bilateral hearing
loss, suggesting that both ears could be involved in the occurrence of
the spells. Previous studies defined two phases in the natural
evolution of episodes of vertigo in MD: the first eight years with
more crises in the initial four years, and a second phase which
extend from 9 to 20 years with a stable frequency of episodes [19].
Our Kaplan-Meier analyses demonstrate that the time-course of
episodes of vertigo is different in patients with unilateral and
bilateral SNHL, suggesting that the condition causing the episodes
may persist for a longer period of time in cases with bilateral SNHL.
Autoimmune inner ear disease (AIED) is a syndrome of rapidly
progressive, often fluctuating, bilateral SNHL over a period of
weeks to months. Vestibular symptoms may be present in almost
50% of patients and systemic AD coexists in 15–30% of patients
[24]. In some cases, AIED begins as sudden SNHL in one ear
progressing rapidly to the second ear with tinnitus and balance
symptoms which may resemble MD [25]. Currently, there is not
biological marker for diagnosis of AIED or MD, but immune
dysfunction is increasingly being recognized in MD. Patients with
AIED treated with corticosteroids may improve SNHL in 50%
cases at short term and in 14% after 34 months [26], so the
response to steroids is not a reliable criteria to exclude MD,
according to the AAO-HNS guidelines [18]. We have found an
increase of systemic AD in patients with MD in our series (RA,
SLE and AS). For RA and AS, the estimated prevalence in
patients with MD was 2–3 times more common [27], but for SLE
the prevalence was 8 times more frequent [28]. Although small
series of patients with SLE has described cases with SNHL, vertigo
is not a usual symptom in these patients. A recent study described
a high-frequency SNHL and abnormal findings in vestibular
testing in a series of patients with AS, but this findings do not fullfill
the criteria for diagnosis of MD [29].
We propose that AIED would be a continuum that would include
sudden SNHL, rapidly progressive SNHL or MD that could be
associated with other autoimmune conditions such as systemic AD.
Moreover, systemic ADs were most commonly observed in patients
with MD and migraine than in cases with MD and tension-type
headache. This finding suggests that AD should be considered in all
cases, but especially in patients with MD and migraine. Further studies
are needed to confirm the spectrum of MD-AD-migraine.
Our data show that an immunological panel including ANA,
Igs, C3, C4, CIC, TNF and INF can not be used as biological
marker for diagnosis of patients with AIED or predictor for uni or
bilateral SNHL. Although several reports found elevated CIC
in 54–96% of patients with MD using a polyethylene glycol
precipitation assay [10,30], another study using our method, a
solid phase immunosorbent assay (ELISA) for C1q and IgG also
found an elevation of CICs in 4% of 49 patients with MD [31].
Our data confirm this study and found elevated CIC in 8% of 422
patients. Moreover, subanalysis of patients with uni or bilateral
MD did not show a higher frequency of elevated CIC. Our data
cannot support that pathophysiology of MD is different in patients
with uni or bilateral involvement, although patients with bilateral
SNHL display a more severe disease.
Finally, we had shown that bilaterality and SNHL at diagnosis are
stronger predictors of hearing levels during follow-up. Moreover,
lymphocytes B are associated with the hearing level and CD8+ T
lymphocytes are associated with the recurrence of vertigo, suggesting
that the immune response may determine the outcome of MD.
CD4+ T lymphocytes predominate in the endolymphatic sac, while
CD8+ T lymphocytes are normally scanty, but the relationship
between CD4+ and CD8+ T cells may be inverted in case of chronic
antigen stimulation, as in the presence of acoustic neuroma [32].
Monitoring the CD4+ and CD8+ T lymphocytes during the spells of
vertigo could help to define AIED and MD.
Despite some limitations of a case series of MD, our study has
found a higher prevalence of systemic AD within patients with
MD. Moreover, these patients are more likely to have migraine
and they may represent an endophenotype within MD. Additional
muticenter studies should confirm the high prevalence of SLE, RA
and AS and the relationship with migraine.
Conclusions
N Patients with MD display an elevated prevalence of systemic
ADs such as RA, SLE and AS.
N AD was more frequent in patients with MD and migraine,
despite the prevelance of migraine in MD in our series does
not differ from the observed prevalence in the general
population.
N B lymphocytes are related with hearing loss and and CD8+ T
lymphocytes with persistence of vertigo, suggesting a role for
the immune response in the activity and progression of MD.
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